Lewes, DE -- (SBWIRE) -- 03/03/2016 -- The treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%, according to new research.

The company's latest report states that this substantial growth, which will occur across the countries of China, India, Japan and Australia, will be driven by the rapidly expanding prevalence population resulting from increasingly aging populations and sedentary lifestyles. Higher diagnosis and treatment rates, due to rising disease awareness among the public, will also play a role.

According to Senior Analyst says: "T2DM is becoming an increasingly common problem in APAC regions as they become more industrialized and diets become more Westernized. In line with this, there is a very large and innovative pipeline, suggesting a strong potential for unmet needs to be addressed in coming years.

"The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes in comparison to currently marketed products. This suggests that unmet needs relating to patient convenience and ease of use will be addressed most significantly over the forecast period."

Publisher also states that the recently approved drug classes, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, are expected to increase their market share by 2021.

Senior Analyst continues: "In comparison to many previously marketed therapies, the new drug classes provide beneficial effects such as improved weight control and lowered hypoglycemia risk. Furthermore, a recent study also identified cardiovascular risk reduction with Jardiance, an SGLT-2 inhibitor.

"These treatments have already achieved strong market uptake, which is expected to increase over the forecast period. The recently launched products in the APAC region that are expected to contribute most significantly to market growth include Forxiga, Invokana, and Jardiance; DPP-4 inhibitors - Zafatek, and Tenglyn/Ziten."

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth report provides analysis of the Type 2 Diabetes Mellitus (T2DM) treatment arena in the Asia-Pacific (APAC) countries of China, India, Japan, and Australia. It includes annualized market data from 2014 and forecast to 2021, highlights current unmet needs, and discusses the current clinical and commercial landscape of the APAC T2DM therapeutics space.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher's team of industry experts.

For more information Visit at: http://www.marketresearchreports.com/gbi-research/type-2-diabetes-mellitus-therapeutics-asia-pacific-markets-2021-increasing-usage-newer

Related Report:

Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation - visit at: http://www.marketresearchreports.com/gbi-research/frontier-pharma-parkinson%E2%80%99s-disease-identifying-and-commercializing-first-class

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions